Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

MLA

Frigault, Matthew J., et al. “Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 1023. EBSCOhost, https://doi.org/10.1182/blood-2023-189761.

APA

Frigault, M. J., Rosenblatt, J., Dhakal, B., Raje, N. S., Cook, D., Gaballa, M., Emmanuel-Alejandro, E., Nissen, D., Banerjee, K. C., Rotte, A., Heery, C. R., Avigan, D., Jakubowiak, A. J., & Bishop, M. R. (2023). Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients. Blood, 142(1, Number 1 Supplement 1), 1023. https://doi.org/10.1182/blood-2023-189761

Chicago

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, Noopur S. Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, et al. 2023. “Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients.” Blood 142 (1, Number 1 Supplement 1): 1023. doi:10.1182/blood-2023-189761.